- Home
- PBYI vs LCTX Comparison
PBYI vs LCTX Comparison
Compare PBYI & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBYI
- LCTX
- Stock Information
- Founded
- PBYI 2010
- LCTX 1990
- Country
- PBYI United States
- LCTX United States
- Employees
- PBYI N/A
- LCTX N/A
- Industry
- PBYI Biotechnology: Pharmaceutical Preparations
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PBYI Health Care
- LCTX Health Care
- Exchange
- PBYI Nasdaq
- LCTX Nasdaq
- Market Cap
- PBYI 171.7M
- LCTX 274.0M
- IPO Year
- PBYI N/A
- LCTX N/A
- Fundamental
- Price
- PBYI $4.47
- LCTX $1.34
- Analyst Decision
- PBYI Strong Buy
- LCTX Strong Buy
- Analyst Count
- PBYI 1
- LCTX 4
- Target Price
- PBYI $7.00
- LCTX $4.25
- AVG Volume (30 Days)
- PBYI 684.0K
- LCTX 1.6M
- Earning Date
- PBYI 11-06-2025
- LCTX 11-13-2025
- Dividend Yield
- PBYI N/A
- LCTX N/A
- EPS Growth
- PBYI 434.29
- LCTX N/A
- EPS
- PBYI 0.97
- LCTX N/A
- Revenue
- PBYI $238,062,000.00
- LCTX $10,914,000.00
- Revenue This Year
- PBYI N/A
- LCTX N/A
- Revenue Next Year
- PBYI N/A
- LCTX $178.80
- P/E Ratio
- PBYI $4.60
- LCTX N/A
- Revenue Growth
- PBYI 8.63
- LCTX 76.43
- 52 Week Low
- PBYI $2.32
- LCTX $0.37
- 52 Week High
- PBYI $6.07
- LCTX $1.42
- Technical
- Relative Strength Index (RSI)
- PBYI 45.38
- LCTX 64.60
- Support Level
- PBYI $4.49
- LCTX $1.20
- Resistance Level
- PBYI $5.22
- LCTX $1.28
- Average True Range (ATR)
- PBYI 0.28
- LCTX 0.07
- MACD
- PBYI -0.13
- LCTX 0.00
- Stochastic Oscillator
- PBYI 5.83
- LCTX 69.64
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.